MiniMed initiated with a Buy at BTIG

BTIG analyst Marie Thibault initiated coverage of MiniMed (MMED) with a Buy rating and $25 price target The firm says MiniMed is the diabetes technology industry’s only “full-stack” company, owning the continuous glucose monitor, insulin pump, algorithm, and software needed to deliver a complete automated insulin delivery system. The company is targeting an over $18B addressable marketed that is growing at a double-digit annual rate that remains just 7% penetrated, the analyst tells investors in a research note.